Incyte (INCY) Change in Accured Expenses (2010 - 2026)
Incyte's (INCY) quarterly Change in Accured Expenses came in at -$204.3 million in Q2 2026, up 57.14% YoY from -$130.0 million in Q2 2025, and down 141.16% on a QoQ basis from -$84.7 million in Q1 2026.
Analysis
Incyte (INCY) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Change in Accured Expenses data on file, last reported at -$204.3 million in Q2 2026.
- Quarterly Change in Accured Expenses rose 57.14% year-over-year to -$204.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$35.4 million (up 76.48% YoY) and the FY2025 annual result came in at -$148.2 million, down 153.13% from the prior year.
- Change in Accured Expenses eased to -$204.3 million in Q2 2026, from -$84.7 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $138.5 million in Q4 2025 to a low of -$476.7 million in Q2 2025.
- A 5-year average of $16.2 million and a median of $62.8 million in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 2430.46% — and 2025, when it plunged 510.9%.
- Tracing INCY's Change in Accured Expenses over 5 years: stood at $47.8 million in 2022, then jumped by 143.08% to $116.2 million in 2023, then gained by 11.66% to $129.8 million in 2024, then rose by 6.76% to $138.5 million in 2025, then sank by 247.48% to -$204.3 million in 2026.
- The last three Change in Accured Expenses figures came in at -$204.3 million (Q2 2026), -$84.7 million (Q1 2026), and $138.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | -204.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -204.33 Mn |
| Mar 31, 2026 | -84.73 Mn |
| Dec 31, 2025 | 138.55 Mn |
| Sep 30, 2025 | 115.14 Mn |
| Jun 30, 2025 | -476.73 Mn |
| Mar 31, 2025 | 74.84 Mn |
| Dec 31, 2024 | 129.77 Mn |
| Sep 30, 2024 | 121.74 Mn |
| Jun 30, 2024 | -78.04 Mn |
| Mar 31, 2024 | 105.47 Mn |
| Dec 31, 2023 | 116.22 Mn |
| Sep 30, 2023 | 21.89 Mn |
| Jun 30, 2023 | 20.60 Mn |
| Mar 31, 2023 | 71.90 Mn |
| Dec 31, 2022 | 47.81 Mn |
| Sep 30, 2022 | 120.73 Mn |
| Jun 30, 2022 | -2.14 Mn |
| Mar 31, 2022 | 53.79 Mn |
| Dec 31, 2021 | 46.40 Mn |
| Sep 30, 2021 | 91.42 Mn |